Velimogene aliplasmid(Velimogene aliplasmid) - 药物靶点：B2M x HLA-B_专利_临床

概要

基本信息

药物类型

基因疗法

别名

ALLOVECTIN-7、Allovectin、Velimogene aliplasmid (INN/USAN)

+ [3]

靶点

B2M x HLA-B

作用机制

B2M抑制剂(β2微球蛋白抑制剂)、HLA-B抑制剂(major histocompatibility complex, class I, B inhibitors)

治疗领域

肿瘤口颌疾病耳鼻咽喉疾病+ [2]

在研适应症-

非在研适应症

复发性黑色素瘤转移性黑色素瘤头颈部鳞状细胞癌+ [1]

原研机构

Vical, Inc.

在研机构-

非在研机构

Vical, Inc.

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 527925266

来源: *****

关联

5

项与 Velimogene aliplasmid 相关的临床试验

NCT00395070 / Completed临床3期

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment With 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects With Recurrent Metastatic Melanoma

To compare the safety and efficacy of Allovectin-7® versus Dacarbazine (DTIC)or Temozolomide (TMZ) in subjects with recurrent stage 3 or stage 4 melanoma.

开始日期2006-10-01

申办/合作机构

Vical, Inc.

NCT00044356 / Completed临床2期

A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.

开始日期2001-02-01

申办/合作机构

Vical, Inc.

NCT00003646 / Completed临床2期

Phase II Study of Allovectin-7 as an Immunotherapeutic Agent in Patients With Stages III and IV Melanoma

RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells.
PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.

开始日期1998-08-01

申办/合作机构

Vical, Inc.

100 项与 Velimogene aliplasmid 相关的临床结果

登录后查看更多信息

100 项与 Velimogene aliplasmid 相关的转化医学

登录后查看更多信息

100 项与 Velimogene aliplasmid 相关的专利（医药）

登录后查看更多信息

22

项与 Velimogene aliplasmid 相关的文献（医药）

2017-08-01·Melanoma Research4区 · 医学

Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report

4区 · 医学

Article

作者: Simone M. Goldinger ; Reinhard Dummer ; Lars E. French ; Pascale Kränzlin-Stieger ; Carla Murer

Treatment of melanoma remains a challenge in advanced disease. Recently, the molecular differentiation in BRAF-mutated, NRAS-mutated and c-kit-mutated melanomas led to new treatment strategies. Different trials show that imatinib or nilotinib lead to meaningful responses in c-kit-mutated melanoma patients. There are little published data on sequential inhibition using these two drugs in melanoma. We describe the sequential use of imatinib after nilotinib in a c-kit-mutated melanoma patient, who progressed on interferon, Allovectin, dacarbazine, nilotinib and ipilimumab, and was finally treated with the c-kit inhibitor imatinib. From July 2011 to September 2011, the patient received ipilimumab (four doses with 3 mg/kg). Clinical assessment after immunotherapy showed disease progression. Therefore, a treatment change to imatinib 800 mg daily was made from February 2012 to May 2013. Under this treatment, the patient showed a partial response as per the RECIST criteria. The present lesions continued responding (computed tomography scans: May 2012–March 2013). Unfortunately, in October 2012, new brain metastases developed. Nevertheless, the use of c-kit inhibitors in c-kit-mutated melanoma patients seems to be a promising treatment option. Furthermore, a delayed response to ipilimumab after 6 months could also have led to or supported the partial response in this case. However, when two biologically similar compounds are administered in a melanoma patient and the tumour mass shows progressive disease upon administration of the first agent, an additional progression with no effect may be expected when the second one is used. This case shows, in contrast, that the use of imatinib after progression upon nilotinib can be beneficial.

2015-03-01·Current Opinion in Oncology3区 · 医学

promise and limitation

3区 · 医学

Review

作者: Agarwala, Sanjiv S

PURPOSE OF REVIEWPatients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma have a high risk for recurrence, progression and metastasis. The article reviews treatment advances for this population.RECENT FINDINGSAfter promising phase 2 results with Allovectin-7 (velimogene aliplasmid), overall survival in a phase 3 study was shorter for Allovectin-7 than for dacarbazine/temozolomide (median 18.8 versus 24.1 months).In a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 among 28 patients with advanced melanoma, the primary endpoint of best overall response rate within 24 weeks of first treatment was 32.2% for objective response and 10.7% for complete response.In the phase 3 OPTiM trial of talimogene laherparepvec, the intralesional agent that is furthest along in clinical testing, the primary endpoint of durable response rate was 16% for talimogene laherparepvec and 2% for granulocyte macrophage colony-stimulating factor.In the PV-10 phase 2 trial among 80 patients with stage III-IV melanoma, the overall response rate was 51%, with a 26% complete response rate.SUMMARYDespite advances, many patients will need several lines of therapy. Some will not be eligible for systemic therapy. Their low toxicity, easy administration and likely systemic immune effects make intralesional therapies an attractive option.

2013-10-01·Clinical Cancer Research

A Sea Change in Melanoma

Article

作者: Bates, Susan E.

As this issue of Clinical Cancer Research goes to press, Vical, Inc., a pharmaceutical company developing an intralesional gene therapy for melanoma, Allovectin-7, announced its decision to discontinue development following negative results in a phase III trial ([1][1]). This story highlights the

1

项与 Velimogene aliplasmid 相关的新闻（医药）

2007-12-05

·BioSpace

John Wayne Cancer Institute: Allovectin-7® May Offer Patients a New Option for Advanced Melanoma

SANTA MONICA, Calif.--(BUSINESS WIRE)--Skin cancer specialists at The John Wayne Cancer Institute at Saint John’s Health Center are recruiting patients into a large Phase 3 study to evaluate the safety and effectiveness of Allovectin-7®, an investigational product for advanced melanoma. If Allovectin-7® is found to be safe and effective in clinical trials, it may offer patients a new option for fighting advanced melanoma (stage 3 or stage 4). Safety and efficacy data from a Phase 2 clinical trial of Allovectin-7® were presented at the 2006 American Society of Clinical Oncology (ASCO) meeting. The ongoing Phase 3 study is designed to determine whether more patients with advanced melanoma respond favorably to Allovectin-7® alone than to current standard chemotherapy alone. To find out whether you or someone you know qualifies for the study, please visit

ASCO会议

100 项与 Velimogene aliplasmid 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09030	-	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头颈部鳞状细胞癌	临床3期	美国	Vical, Inc.	2002-12-09
口咽部鳞状细胞癌	临床3期	美国	Vical, Inc.	2002-12-09
复发性黑色素瘤	临床3期	美国	Vical, Inc.	1998-07-01
转移性黑色素瘤	临床3期	美国	Vical, Inc.	1998-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2012	临床2期	转移性黑色素瘤	127	velimogene aliplasmid (Clinical Benefit (CB))	(範鬱築鹽淵夢鹽糧淵選) = 鹽網選獵鏇窪觸窪蓋窪蓋積膚範壓獵鹽壓鬱膚 (願艱淵構顧襯壓繭艱廠, 6.2 ~ 17.4) 更多	-	2012-05-20
ASCO2012	临床2期	转移性黑色素瘤	127	velimogene aliplasmid (Progressive Disease (PD))	(齋餘衊蓋遞網遞艱壓蓋) = 簾醖壓餘淵鹽範製獵襯糧網繭鑰繭鬱蓋艱衊夢 (鏇膚醖願襯遞憲範鬱憲 )	-	2012-05-20
ASCO2011	临床2/3期	黑色素瘤	-	Allovectin 2 mg	(鬱遞淵鹽範獵獵範築選) = 觸糧繭簾鬱衊積鹽選壓鹹憲艱繭糧蓋齋壓蓋選 (繭構範鑰鹹齋積憲鹹夢 ) 更多	积极	2011-05-20
ASCO2005	临床2期	转移性黑色素瘤	133	Allovectin-7	(築夢鬱繭襯淵遞襯膚壓) = 鏇艱製獵顧構遞蓋選積糧構襯觸夢淵醖構窪積 (淵窪夢餘網鏇積鏇鹽壓, 8.3 ~ ongoing) 更多	-	2005-06-01
ASCO2004	临床2期	转移性黑色素瘤	133	Allovectin-7	(願鹹夢壓鏇鹹繭鑰網獵) = One Grade 3 adverse event associated with A-7 have been reported 遞簾鹽遞積衊積鬱獵鹹 (願糧選簾壓襯鹹衊網餘 ) 更多	-	2004-07-15